{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Rathkopf DE"],"funding":["GlaxoSmithKline","Daiichi Sankyo Europe","U.S. Department of Defense","NCI NIH HHS","Prostate Cancer Foundation","Bristol-Myers Squibb Company"],"pagination":["76-88"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12094577"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["36(1)"],"pubmed_abstract":["Background
Metastatic castration-resistant prostate cancer (mCRPC) that progresses on androgen receptor pathway inhibitors (ARPIs) may continue to be driven by AR signaling. BMS-986365 is an orally administered ligand-directed degrader targeting the AR via a first-in-class dual mechanism of AR degradation and antagonism. CC-94676-PCA-001 (NCT04428788) is a phase I multicenter study of BMS-986365 in patients with progressive mCRPC.Patients and methods
Patients who progressed on androgen deprivation therapy, one or more ARPIs, and taxane chemotherapy (unless declined/ineligible) were enrolled. The study included dose escalation (part A) and expansion (part B) of BMS-986365 up to 900 mg twice daily. Primary objectives were safety and tolerability, and to define maximum tolerat"],"journal":["Annals of oncology : official journal of the European Society for Medical Oncology"],"pubmed_title":["Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer."],"pmcid":["PMC12094577"],"funding_grant_id":["P30 CA016672","P30 CA008748","P30 CA014236"],"pubmed_authors":["Wu J","Pourdehnad M","Emamekhoo H","Arora VK","Kandimalla R","Rathkopf DE","Wells AL","Runcie KD","Hawley JE","Suryawanshi S","Reichert ZR","Narayan V","Patel MR","Lakhani N","Liu C","Han J","Rasco D","Srinivas S","Nguyen MH","Armstrong AJ","Choudhury AD","Aparicio A"],"additional_accession":[]},"is_claimable":false,"name":"Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer.","description":"Background
Metastatic castration-resistant prostate cancer (mCRPC) that progresses on androgen receptor pathway inhibitors (ARPIs) may continue to be driven by AR signaling. BMS-986365 is an orally administered ligand-directed degrader targeting the AR via a first-in-class dual mechanism of AR degradation and antagonism. CC-94676-PCA-001 (NCT04428788) is a phase I multicenter study of BMS-986365 in patients with progressive mCRPC.Patients and methods
Patients who progressed on androgen deprivation therapy, one or more ARPIs, and taxane chemotherapy (unless declined/ineligible) were enrolled. The study included dose escalation (part A) and expansion (part B) of BMS-986365 up to 900 mg twice daily. Primary objectives were safety and tolerability, and to define maximum tolerat","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jan","modification":"2026-06-12T05:20:58.422Z","creation":"2026-06-12T03:08:21.128Z"},"accession":"S-EPMC12094577","cross_references":{"pubmed":["39293515"],"doi":["10.1016/j.annonc.2024.09.005"]}}